Bruker Corporation (NASDAQ:BRKR) Announces $0.05 Quarterly Dividend

Bruker Corporation (NASDAQ:BRKR) announced a quarterly dividend on Thursday, February 19th. Shareholders of record on Monday, March 23rd will be paid a dividend of 0.05 per share by the medical research company on Tuesday, April 7th. This represents a c) annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, March 23rd.

Bruker has increased its dividend by an average of 0.0%per year over the last three years. Bruker has a dividend payout ratio of 7.3% indicating that its dividend is sufficiently covered by earnings. Analysts expect Bruker to earn $3.15 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 6.3%.

Bruker Trading Down 0.9%

Bruker stock opened at $33.33 on Friday. Bruker has a one year low of $28.53 and a one year high of $56.22. The company has a market cap of $5.07 billion, a price-to-earnings ratio of -222.17, a P/E/G ratio of 2.01 and a beta of 1.19. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The firm has a 50-day moving average of $41.57 and a 200-day moving average of $41.00.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. During the same quarter in the prior year, the business earned $0.76 earnings per share. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts expect that Bruker will post 2.69 earnings per share for the current fiscal year.

Insider Activity at Bruker

In other Bruker news, VP Mark Munch sold 7,000 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 11,000 shares of company stock valued at $554,280 over the last quarter. 27.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BRKR. Los Angeles Capital Management LLC bought a new position in shares of Bruker during the 4th quarter worth about $26,000. Allworth Financial LP increased its stake in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Parallel Advisors LLC raised its holdings in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the last quarter. Spire Wealth Management lifted its stake in shares of Bruker by 85.3% in the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after buying an additional 665 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Bruker in the 4th quarter valued at about $50,000. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.